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Gainesville, Florida
Objectives The purpose of this study was to summarize the evidence of pre-procedural statin therapy to reduce periproce-
dure cardiovascular events.
Background Invasive procedures can result in adverse cardiovascular events, such as myocardial infarction (MI) and death.
We hypothesized that statins might improve clinical outcomes when used before invasive procedures.
Methods We searched the MEDLINE, Cochrane, and clinicaltrials.gov databases from inception to February 2010 for ran-
domized, controlled trials that examined statin therapy before invasive procedures. Invasive procedures were
defined as percutaneous coronary intervention, coronary artery bypass grafting (CABG), and noncardiac surgery.
We required that studies initiated statins before the procedure and reported clinical outcomes. A DerSimonian-
Laird model was used to construct random-effects summary risk ratios.
Results Eight percent of the screened trials (21 of 270) met our selection criteria, which included 4,805 patients. The
use of pre-procedural statins significantly reduced post-procedural MI (risk ratio [RR]: 0.57, 95% confidence
interval [CI]: 0.46 to 0.70, p  0.0001). This benefit was seen after both percutaneous coronary intervention
(p  0.0001) and noncardiac surgical procedures (p  0.004), but not CABG (p  0.40). All-cause mortality
was nonsignificantly reduced by statin therapy (RR: 0.66, 95% CI: 0.37 to 1.17, p  0.15). Pre-procedural
statins also reduced post-CABG atrial fibrillation (RR: 0.54, 95% CI: 0.43 to 0.68, p  0.0001).
Conclusions Statins administered before invasive procedures significantly reduce the hazard of post-procedural MI. Addition-
ally, statins reduce the risk of atrial fibrillation after CABG. The routine use of statins before invasive procedures
should be considered. (J Am Coll Cardiol 2010;56:1099–109) © 2010 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.04.023t
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Snvasive procedures carry an inherent risk of adverse cardio-
ascular events including myocardial infarction (MI) and
eath. These events are not uncommon, and when they
ccur, they are associated with poor clinical outcomes after
oth percutaneous and surgical procedures (1–4).
To reduce the risk of adverse events associated with
nvasive procedures, various interventions have been inves-
igated. For example, beta-blockers have been recom-
ended in high-risk patients undergoing noncardiac sur-
ery (5). However, an updated systematic analysis indicates
hat although this approach may decrease MI, it comes at a
ost of increased nonfatal strokes, with no effect on mortal-
ty (6). Similarly, pre-operative cardiac stress testing fol-
owed by possible coronary revascularization remains con-
rom the *Division of Cardiovascular Medicine, University of Florida, Gainesville,
lorida; †Department of Epidemiology and Health Policy Research, University of
lorida, Gainesville, Florida; and the ‡College of Medicine, University of Florida,
ainesville, Florida. Supported by an unrestricted grant from the Florida Heart Research
nstitute. All authors have reported that they have no relationships to disclose.g
Manuscript received February 8, 2010; revised manuscript received March 23,
010, accepted April 5, 2010.roversial as this approach has not been shown to decrease
he incidence of periprocedural adverse events (7,8).
See page 1110
Statins have been demonstrated to be beneficial when
tarted during an acute coronary syndrome (ACS) (9–11);
owever, in most of these trials, the statin was started after
ercutaneous coronary intervention (PCI). Recent publica-
ion of randomized trials specifically exploring the role of
tatin therapy given before invasive procedures, including
CI and surgery, have added to the available evidence of
his important clinical question (12,13). Accordingly, we
ought to perform a comprehensive meta-analysis to evalu-
te whether statins administered before invasive procedures
ight reduce adverse cardiovascular events.
ethods
election criteria. We selected studies of patients under-
oing an invasive procedure with randomization to statin
c
u
p
c
2
h
o
v
a
L
M
s
c
W
g
w
M
O
p
p
k
t
p
a
i
a
i
t
p
s
u
D
a
r
d
m
i
i
f
n
n
I
s
g
1100 Winchester et al. JACC Vol. 56, No. 14, 2010
Pre-Procedural Statin Therapy September 28, 2010:1099–109therapy versus control, in which
control could be: 1) placebo; 2)
usual care; or 3) lower dose statin
therapy. Invasive procedures were
defined as PCI, coronary artery
bypass grafting (CABG), or non-
cardiac surgical procedures includ-
ing vascular surgery. We required
that study medications were initi-
ated before the procedure and that
clinical outcome data were reliably
reported. To maximize search sen-
sitivity, we used the term percuta-
neous transluminal coronary an-
gioplasty; however, to focus on
ontemporary practice, we excluded trials that did not routinely
se stents. We excluded studies that examined organ trans-
lantation. Select data from previous meta-analyses that in-
luded patient level data were used. In studies with more than
intervention groups or 2  2 factorial designs, we used the
ighest dose statin group versus the lowest dose control group
r placebo, if available. We excluded trials of multiple inter-
entions in which the statin intervention could not be isolated
nd compared with a placebo or standard care group.
iterature review. A computerized literature search of the
EDLINE database was conducted without language re-
triction from inception until February 2010 for randomized
linical trials using the search strategy shown in Figure 1.
e also searched the Cochrane database and Clinicaltrials.
ov using the MeSH terms and keywords listed in Figure 1,
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CABG  coronary artery
bypass grafting
CI  confidence interval
CK-MB  creatine kinase-
myocardial band
MI  myocardial infarction
PCI  percutaneous
coronary intervention
RR  risk ratio
Figure 1 Study Selection Flow Diagram
Summary of how the systematic search was conducted and eligible studies were i
PCI  percutaneous coronary intervention; PTCA  percutaneous transluminal corhich did not identify any additional studies beyond
EDLINE.
utcomes and definitions. The primary outcome was
ost-procedural nonfatal MI. In PCI trials, a post-
rocedural event was defined as an elevation of the creatine
inase-myocardial band (CK-MB) assay more than 2 to 3
imes the upper limit of normal within 12 to 24 h after the
rocedure. In surgical trials, post-operative MI was defined
s a Q-wave MI during hospitalization.
Secondary outcomes were all-cause mortality, revascular-
zation, and atrial fibrillation. Revascularization was defined
s ischemic symptoms that resulted in a repeat revascular-
zation procedure. New-onset post-operative atrial fibrilla-
ion was confirmed by 12-lead electrocardiogram and was
ersistent for several minutes. When multiple time in-
tances of atrial fibrillation were reported, we preferentially
sed the earlier outcome.
ata extraction. Data were independently extracted by 3
uthors (D.E.W., L.X., A.A.B.). Any discrepancies were
esolved by consensus of the authors. When necessary for
ata or article clarification, personal communication was
ade with select study authors. Baseline patient character-
stics were extracted as well as data about each trial’s
ntervention, previous statin treatment, and duration of
ollow-up. For all clinical outcomes, we tabulated the
umber of events that occurred in each arm of each trial. For
on-English articles, we used Google Translator (Google,
nc., Mountain View, California) when possible and re-
earch associates who are native speakers of foreign lan-
uages otherwise.
ed. CABG  coronary artery bypass grafting;
ngioplasty.dentifi
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September 28, 2010:1099–109 Pre-Procedural Statin Therapytatistical analysis. We analyzed outcomes by the
ntention-to-treat method. Cholesterol data were analyzed
y Student paired t test. A DerSimonian-Laird model was
sed to construct random-effects summary risk ratios (RRs).
e assessed for heterogeneity between studies by calculat-
ng a Cochran’s Q statistic and an I2 statistic and for
ublication bias by Beggs’ and Egger’s methods (14). To
xplore the effect of pre-selected covariates on the overall
reatment effect, we performed a random-effects meta-
egression analysis (15). The logarithm of relative risk for
I, weighted by the inverse variance of each study, was
egressed against type of statin, mean reduction in low-
ensity lipoprotein cholesterol in the treatment group, and
he number of days before the procedure that statin therapy
as initiated. Trial quality was assessed based on the
dequate description of treatment allocation, blinded out-
ome assessment, and description of losses to follow-up
16). We followed the PRISMA statement for conducting a
igh-quality meta-analysis (17). All p values were 2-tailed,
ith statistical significance set at 0.05, and confidence
ntervals (CIs) were calculated at the 95% level. All analyses
ere performed using STATA software version 11
STATA Corporation, College Station, Texas).
esults
aseline characteristics. A total of 270 abstracts were
elected for further screening. Figure 1 shows our search
trategy, which yielded 21 studies with 4,805 patients
aseline Characteristics and Follow-Up DurationTable 1 Baseline Characteristics and Follow-Up Duration
First Author/Trial (Ref. #) Year Patients, n Age, yrs
Yun et al. (18) 2009 225/220 64/63
Veselka et al. (19) 2009 100/100 68/64
NAPLES II (20) 2009 338/330 64/65
Jia et al. (21) 2009 113/115 65/66
ARMYDA–RECAPTURE (22) 2009 192/191 66/66
ARMYDA–ACS (23) 2007 86/85 64/67
Kinoshita et al. (24) 2007 21/21 66/67
Bozbas et al. (25) 2007 29/34 57/62
ARMYDA (12) 2004 76/77 64/65
Briguori et al. (26) 2004 226/225 63/62
Ji et al. (27) 2009 71/69 65/66
Berkan et al. (28) 2009 23/23 65/68
Mannacio et al. (29) 2008 100/100 61/59
Song et al. (30) 2008 62/62 62/64
Tamayo et al. (31) 2008 22/22 68/68
ARMYDA-3 (32) 2006 101/99 66/67
Chello et al. (33) 2006 20/20 66/64
Christenson et al. (34) 1999 40/37 63/64
DECREASE-III (13) 2009 250/247 66/66
DECREASE-IV (35) 2009 265/268 65/66
Durazzo et al. (36) 2004 50/50 66/68
ata are formatted as statin arm/control arm. *Percentage of patients with DM was not reported;
on–ST-segment elevation myocardial infarction, and 29% had ST-segment elevation myocardial infarcti
ACS  acute coronary syndrome; CABG  coronary artery bypass grafting; DM  diabetes mellitus; NR12,13,18–36). PCI was usually performed in an elective
etting; however, 4 studies included ACS patients (18,21–23)
Table 1). Various statin drugs and doses were used
Table 2). All patients were statin naïve except for 1 study
hat included patients on long-term statin therapy (22). In
he PCI studies, open-label statin was administered after
evascularization, whereas in the noncardiac surgical studies,
tudy assignment was maintained to 30 days of follow-up.
easures of study quality are shown in Table 3. Summa-
ized cholesterol data are shown in Table 4.
ost-procedural MI. All PCI studies defined MI as 2 to 3
imes the upper limit of normal for CK-MB, although 1
tudy used a definition of CK-MB greater than the upper
imit of normal (25). Most surgical studies required new
ppearance of Q waves; however, 2 studies defined MI as
ither a Q-wave MI or an elevation in troponin T more than
he upper limit of normal (13,35) and 1 study did not define
I (27).
Post-procedural MI was reduced by pre-procedural statin
herapy compared with control (RR: 0.57, 95% CI: 0.46 to
.70, p  0.0001) (Fig. 2). Cochran’s Q-statistic for
eterogeneity was 13.03 (p  0.73), with no evidence of
ublication bias by Egger’s test (p  0.14) or Begg’s funnel
lot (Fig. 3). In the PCI cohort, the incidence of post-
rocedural MI was 7.5% with statin therapy versus 13.3%
ith control (p  0.0001). When the PCI analysis was
estricted to trials that defined periprocedural MI as a
K-MB3 times the upper limit of normal (instead of 2 to
times), the reduction in MI persisted (RR: 0.67, p 
DM, % Patient Population Follow-Up Duration
33/30 Urgent PCI for ACS 30 days
26/25 Elective PCI 1 day
39/37 Elective PCI 1 day
19/22 Urgent PCI for ACS* 1 day
37/35 Elective PCI or urgent PCI for ACS† 30 days
29/33 Urgent PCI for ACS 30 days
NR‡ Elective PCI 6 months
17/21 Elective PCI 1 day
27/19 Elective PCI 30 days
25/19 Elective PCI 1 day
38/38 Elective off-pump CABG 13 days
35/39 Elective CABG 30 days
0/0 Elective CABG 23 days
47/52 Elective off-pump CABG 30 days
27/41 Elective CABG 2.5 days
32/42 Elective CABG 30 days
0/0 Elective CABG 7 days
23/24 Elective CABG 12 days
22/17 Elective vascular surgery 30 days
12/9 Elective noncardiac surgery 30 days
18/16 Elective vascular surgery 6 months
er, mean hemoglobin A1C was 5.7% and 5.4%, respectively. †44% had unstable angina, 26% hadhowev
on. ‡53% had stable angina and 47% had non–ST-segment elevation myocardial infarction.
 not reported; PCI  percutaneous coronary intervention.
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Pre-Procedural Statin Therapy September 28, 2010:1099–109.003). In the CABG cohort, post-operative MI was 1.4%
ersus 2.9% (p  0.40), and in the noncardiac surgery
ohort, post-operative MI was 3.5% versus 7.6% (p 
reatment Strategy of Statin TherapyTable 2 Treatment Strategy of Statin Therapy
First Author/Trial (Ref. #) Statin Arm
Yun et al. (18) Rosuvastatin 40 mg, mean 16 h before PCI
Veselka et al. (19) Atorvastatin 80 mg/day, 2 days before PCI
NAPLES II (20) Atorvastatin 80 mg, 1 day before PCI
Jia et al. (21) Simvastatin 80 mg/day, 7 days before PCI
ARMYDA–RECAPTURE (22) Atorvastatin 80 mg, 12 h and 40 mg 2 h before PC
ARMYDA–ACS (23) Atorvastatin 80 mg, 12 h and 40 mg 2 h before PC
Kinoshita et al. (24) Atorvastatin 5–20 mg/day, 2 weeks before PCI*
Bozbas et al. (25) Pravastatin 40 mg/day, 7 days before PCI
ARMYDA (12) Atorvastatin 40 mg/day, 7 days before PCI
Briguori et al. (26) Any statin 3 days before PCI†
Ji et al. (27) Atorvastatin 20 mg/day, 7 days before CABG
Berkan et al. (28) Fluvastatin 80 mg/day, 3 weeks before CABG
Mannacio et al. (29) Rosuvastatin 20 mg/day, 7 days before CABG
Song et al. (30) Atorvastatin 20 mg/day, 3 days before CABG
Tamayo et al. (31) Simvastatin 20 mg/day, 3 weeks before CABG
ARMYDA-3 (32) Atorvastatin 40 mg/day, 7 days before CABG
Chello et al. (33) Atorvastatin 20 mg/day, 3 weeks before CABG
Christenson et al. (34) Simvastatin 20 mg/day, 4 weeks before CABG
DECREASE-III (13) Fluvastatin 80 mg/day, median 37 days before vas
DECREASE-IV (35) Fluvastatin 80 mg/day, median 34 days before no
Durazzo et al. (36) Atorvastatin 20 mg/day, 4 weeks before surgery
In the statin arm, the goal was to achieve a low-density lipoprotein 70 mg/dl and in the contro
g/day), pravastatin 29% (mean dose 32 mg/day), simvastatin 39% (mean dose 24 mg/day),
ercutaneous coronary intervention. ‡Therapy given to all patients unless otherwise described.
ND  not described; other abbreviations as in Table 1.
ssessment of Study Quality ComponentsTable 3 Assessment of Study Quality Components
First Author/Trial (Ref. #)
Trial
Primary Outcome Tr
Yun et al. (18) Post-procedure MI N
Veselka et al. (19) Post-procedure MI N
NAPLES II (20) Post-procedure MI C
Jia et al. (21) Post-procedure MI N
ARMYDA–RECAPTURE (22) Adverse events R
ARMYDA–ACS (23) Adverse events R
Kinoshita et al. (24) Post-procedure MI N
Bozbas et al. (25) Post-procedure MI N
ARMYDA (12) Post-procedure MI N
Briguori et al. (26) Q-wave MI C
Ji et al. (27) Atrial fibrillation C
Berkan et al. (28) Inflammatory markers N
Mannacio et al. (29) Post-operative MI C
Song et al. (30) Atrial fibrillation R
Tamayo et al. (31) Inflammatory markers N
ARMYDA-3 (32) Atrial fibrillation C
Chello et al. (33) Inflammatory markers N
Christenson et al. (34) Thrombocytosis N
DECREASE-III (13) Myocardial ischemia C
DECREASE-IV (35) Adverse events C
Durazzo et al. (36) Adverse events C
ata are formatted as statin arm/control arm. *Double-blind trial; however, no specific mention o
valuation were interpreted in a blinded fashion; however, no specific mention of clinical outcome asses
MI  myocardial infarction; other abbreviation as in Table 2..004), respectively, for statin therapy versus control. The
ndings were strengthened when only placebo-controlled
rials were examined (Fig. 4). Metaregression confirmed no
Control Arm Post-Procedure Statin‡
Usual care Rosuvastatin 10 mg/day
Usual care Statin therapy daily
Usual care Atorvastatin 20 mg/day
Simvastatin 20 mg/day Simvastatin 20 mg/day
Placebo Atorvastatin 40 mg/day
Placebo Atorvastatin 40 mg/day
Atorvastatin 5–20 mg/day* ND
Usual care Pravastatin therapy daily
Placebo Atorvastatin 40 mg/day
Usual care Statin therapy daily
Placebo ND
Placebo ND
Placebo Clinically indicated drugs
Usual care Atorvastatin 20 mg/day
Usual care ND
Placebo Atorvastatin 40 mg/day
Placebo ND
Usual care ND
surgery Placebo Study drug until 30-day follow-up
c surgery Placebo Study drug until 30-day follow-up
Placebo Study drug until 30-day follow-up
oal was 100 mg/dl. †Type and dose determined by operator; atorvastatin 29% (mean dose 22
vastatin 3% (mean dose 80 mg/day). In 84% of patients, statin was started 2 weeks before
eration of
nt Assignment
Blinded Outcome
Assessment
Completeness of
Follow-Up (%)
ND 100/100
No 100/100
ter-generated ND 100/100
ND 100/100
number Double blind* 100/100
number Yes 100/100
ND 95/100
ND 100/100
Double blind* 100/100
ter-generated No 100/100
ter-generated Yes 100/100
Double blind* 100/100
ter-generated Double blind*† 100/100
ization table ND 100/100
ND 100/100
ter generated Yes 100/100
Double blind*† 100/100
ND 100/100
ter-generated ND† ND
ter-generated No ND
ter-generated Yes 100/100
d outcome assessment. †Angiograms, electrocardiograms, echocardiograms, and/or laboratoryI
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September 28, 2010:1099–109 Pre-Procedural Statin Therapyvidence of heterogeneity based on preselected trial charac-
eristics (Table 5, Fig. 5).
dditional outcomes. All-cause mortality was nonsignifi-
antly reduced with pre-procedural statin therapy compared
ith control (RR: 0.66, 95% CI: 0.37 to 1.17, p  0.15)
Fig. 6). Among the PCI studies, repeat revascularization
as not observed in the statin arm, whereas there were 6
evascularizations in the control arm (RR: 0.26, 95% CI:
.06 to 1.24, p  0.09). Among the CABG studies,
ost-operative atrial fibrillation was 19% in the statin arm
ersus 37% in the control arm (RR: 0.54, 95% CI: 0.43 to
.68, p  0.0001) (Fig. 7).
ummary Data on Lipid ReductionTable 4 Summary Data on Lipid Reduction
Treatment
Baseline Follow-Up
LDL cholesterol 126 20.6 96 14.6
Total cholesterol 215 29.2 171 17.2
alues are mean  SD. *Paired t test compared between follow-up and baseline for LDL and tota
LDL  low-density lipoprotein.
Figure 2 RRs for Post-Procedural Myocardial Infarction
Trials that did not report myocardial infarction were excluded from this analysis. Th
indicates the weight of the sample size from each study. CI  confidence interval;iscussion
ur analysis of 21 randomized trials in 4,805 patients shows
hat pre-procedural statin therapy is beneficial. Statin ther-
py initiated approximately 1 to 7 days before PCI reduced
ost-procedural MI, whereas statin therapy initiated ap-
roximately 4 weeks before noncardiac surgical procedures
educed post-operative MI. The absolute risk reduction of
ost-procedural MI was 5.8% after PCI and 4.1% after
oncardiac surgical procedures. Considering all the studies,
hort-term mortality was nonsignificantly reduced. Among
he PCI studies, repeat revascularization was nonsignifi-
Placebo
lue* Baseline Follow-Up p Value*
18 127 19.3 119 11.6 0.098
25 212 23.1 194 11.6 0.20
sterol.
tive size of the data markers
risk ratio; other abbreviations as in Figure 1.p Va
0.00
0.00e rela
RR 
c
l
t
O
p
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Pre-Procedural Statin Therapy September 28, 2010:1099–109antly reduced, and among the CABG studies, atrial fibril-
ation was significantly reduced with pre-procedural statin
herapy.
Figure 3 Funnel Plot
Funnel plot by Begg’s method to assess for publication bias in post-procedural my
Figure 4 RRs for Post-Procedural Myocardial Infarction in Place
Statistical analysis was repeated using only placebo-controlled trials. Trials that di
The relative size of the data markers indicates the weight of the sample size fromptimal statin agent and dose. We demonstrated that
re-procedural statin therapy has robust clinical benefit;
owever, the difficulty in implementing such therapy hinges
al infarction (p  0.14).
ontrolled Trials
report myocardial infarction were excluded from this analysis.
study. Abbreviations as in Figures 1 and 2.ocardibo-C
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September 28, 2010:1099–109 Pre-Procedural Statin Therapyn the type and dose of statin therapy. Both the PCI and
urgical studies used a wide variety of drugs and doses;
owever, in the PCI studies, 56% of the weight of the
nalysis came from trials of atorvastatin40 mg; for CABG
tudies, 58% of the analysis involved atorvastatin 20 mg;
nd for noncardiac surgical trials, 91% of the analysis
nvolved fluvastatin 80 mg.
Interestingly, fluvastatin was able to confer benefit despite
aving the lowest potency. An advantage of fluvastatin is a
ong-acting formation, which the DECREASE (Dutch
chocardiographic Cardiac Risk Evaluation Applying
tress Echocardiography) study investigators stated could
erves as a “bridge” during the post-operative period when
atients were not receiving oral medications. Alternatively,
uring this period, statin medications could be given by the
asogastric route (35). It stands to reason that higher
otency statin therapy would confer more protection around
he time of invasive procedures. The PROVE-IT (Prava-
nivariable Meta-Regression Evaluating for Effect Modification of STable 5 Univariable Meta-Regression Evaluating for Effect Mod
Potential Modifier Trials, n Patient
Days on statin before procedure 16 4,45
Reduction in LDL cholesterol 5 77
Agent
Atorvastatin — —
Rosuvastatin 11 2,68
Simvastatin 10 2,26
Pravastatin 10 2,10
Fluvastatin 12 3,27
DL  low density lipoprotein.
Figure 5 Metaregression Plot
Plot of univariate metaregression examining the effect of duration of statin therapy
on the relationship of statin therapy and post-procedural myocardial infarction (MI)tatin or Atorvastatin Evaluation and Infection Therapy)
rial supports this concept, although in that study, statin
herapy was started after revascularization (37). Only a
edicated trial specifically exploring the relationship of dose
nd type of statin therapy before invasive procedures can
nswer this question. For practice to reflect clinical trials,
torvastatin would be selected before PCI and CABG,
hereas fluvastatin would be selected before noncardiac
urgical procedures.
ptimal timing of statin therapy. It is also unknown how
ong statin therapy should be initiated before invasive
rocedures to achieve benefit. The ARMYDA (Atorvasta-
in for Reduction of MYocardial Damage during Angio-
lasty) trial demonstrated less post-procedural MI with
torvastatin 80 mg/day initiated 1 week before PCI; how-
ver, NAPLES (Novel Approaches for Preventing or Lim-
ting Events) II trial also demonstrated benefit of atorvasta-
in 80 mg initiated just 1 day before PCI. In the PCI trials,
Therapy on Post-Procedure Myocardial Infarctionion of Statin Therapy on Post-Procedure Myocardial Infarction
Relative Risk (95% Confidence Interval) p Value
0.99 (0.97–1.01) per 1-day increment 0.40
0.92 (0.53–1.59) per 10-mg/dl reduction 0.66
Reference —
0.93 (0.42–2.05) 0.84
0.37 (0.03–4.69) 0.40
0.61 (0.10–3.67) 0.55
0.89 (0.43–1.84) 0.73
e the invasive procedure
0.40). Abbreviation as in Figure 2.tatinificat
s, n
8
2
6
9
4
1befor
(p 
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Pre-Procedural Statin Therapy September 28, 2010:1099–109ll patients were given open-label statin after revasculariza-
ion; suggesting that the reduction in MI is attributable to
he pre-procedural use of statins.
None of the surgical trials independently demonstrated
significant reduction in MI; however, DECREASE III
nd IV displayed a trend toward reduced post-operative
I with fluvastatin XL 80 mg initiated 1 month before
urgery. In contrast, ARMYDA-3 did not reveal a benefit
ith atorvastatin 40 mg/day initiated 1 week before PCI,
lthough that study only enrolled 200 patients. In the
oncardiac surgical trials, patients were maintained on
heir treatment assignment until 30-day follow-up. Ac-
ordingly, the reduction in MI in this population may be
combined effect of pre- and post-operative use of
tatins. In sum, these comparisons seem to suggest that
arlier initiation of therapy is an important consideration
n preventing post-procedural MI after elective proce-
ures. For unstable patients, short-term administration
f a high-dose statin may provide clinical benefit without
ecessitating a delay in performing an indicated invasive
rocedure. Again, only a dedicated trial can provide
nsight into how early statins should be started before an
nvasive procedure to confer optimal benefit.
eneficial effects of statins. Autopsy studies demonstrate
he role of plaque rupture and erosion in the pathophysiol-
Figure 6 RRs for Short-Term All-Cause Mortality
Trials that did not report mortality were excluded from this analysis. The relative s
indicate the weight of the sample size from each study. Abbreviations as in Figuregy of ACS (38). Statins have pleiotropic effects, which Cnclude modification of atherosclerotic plaques (39,40) and
mprovement of endothelial function (41–45). Accumulat-
ng data are also highlighting the importance of inflamma-
ion in the pathogenesis of atherosclerosis and the ability of
tatins to reduce inflammatory markers and improve cardio-
ascular events (46–48).
tatin side effects. The studies included in our analysis did
ot report data on adverse statin effects, which precluded us
rom specifically analyzing these outcomes; however, statin
afety has been well documented from other studies. Im-
ortantly, statins do not appear to increase the risk of events
uch as rhabdomyolysis or cancer (49,50). Dedicated studies
f statins in surgical patients have also confirmed the safety
f these drugs post-operatively (51). Because some statins
re metabolized through the cytochrome P-450 system,
here has been concern that these medications might atten-
ate the antiplatelet effects of clopidogrel; however, this
oes not appear to be the case (52). Direct statin effects on
oagulation have also been noted (53), but this has not
ranslated into an increased risk of bleeding (54). In our
nalysis, all-cause mortality was nonsignificantly reduced
rom pre-procedural statin therapy, which supports the
verall safety of these agents during the periprocedure
eriod.
uideline recommendations. Current guidelines for
the data markers
d 2.ize of
s 1 anABG (55), elective PCI (56), and ACS (57) recommend
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September 28, 2010:1099–109 Pre-Procedural Statin Therapytatins for secondary prevention of cardiac events through
isk-factor modification. Guidelines for perioperative car-
iovascular evaluation before noncardiac surgery state that
tatins can be considered for patients with intermediate risk
actors and that it is reasonable to initiate medication before
ascular surgery (5). None of these guidelines specifically
ecommend the use of statins before invasive procedures for the
xpress purpose of preventing periprocedural complications
uch as MI and atrial fibrillation. Our analysis adds strength to
urrent recommendations and potentially expands the use of
hese agents before PCI and surgical procedures.
tudy strengths. A strength of this analysis is the uniform
efinition of MI and follow-up among the PCI studies. For
xample, the PCI studies all reported MI within 1 day.
oreover, nonfatal MI was the primary focus of most of the
CI trials and many of the surgical trials. We also carefully
valuated for heterogeneity by the following means: first,
ur summary estimate is constructed from a random-effects
odel due to the inherent differences in patient populations
nd statins. Second, there was no evidence of overall
eterogeneity with formal statistical testing. Third, there
as no evidence of subtle differences between trials with
etaregression. Specifically, statin type, low-density lipo-
rotein cholesterol reduction from treatment, and the num-
er of days on statin before the procedure did not appear to
ffect the summary estimate.
tudy limitations. We expected one limitation to occur as
result of the control groups being a mixture of placebo and
Figure 7 RRs for Atrial Fibrillation
Trials that did not report atrial fibrillation were excluded from this analysis. Atrial fi
The relative size of the data markers indicates the weight of the sample size fromsual care, sometimes including statins at doses lower than in the intervention groups. However, after restricting the
nalysis to placebo-controlled trials, there was an even
tronger reduction in post-procedural MI, among both the
CI and noncardiac surgery trials. Some of the surgical
tudies explored different primary outcomes, such as inflam-
atory markers; therefore, adjudication of clinical event
ata from these studies might be somewhat less reliable.
ost of the studies were good quality; however, some
tudies did not report generation of treatment assignment or
hether outcomes were assessed in a blinded fashion. There
as no significant reduction in MI after CABG; however,
hese were small trials that represented only 4% of the
eight of the overall analysis. Moreover, the statins in the
ABG studies were lower dose. Therefore, the effect of
tatins in this population remains understudied. Ultimately,
n adequately powered study with long-term follow-up will
e necessary to demonstrate whether pre-procedural statins
ot only reduce MI, but safely reduce mortality across a
ange of invasive procedures.
onclusions
tatin therapy initiated before invasive procedures reduces
ost-procedural MI, after both PCI and noncardiac surgical
rocedures. Statin therapy also reduces post-operative atrial
brillation. Pre-procedural statin therapy should become an
ncreasingly important strategy to improve the safety of
on was only reported in trials of CABG.
study. Abbreviations as in Figures 1 and 2.brillati
eachnvasive procedures.
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